Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT (xanomeline and trospium chloride) in China to treat schizophrenia. The registrational bridging trial, which ...

SE (ARGNF) reports robust product sales growth and a solid cash position, while navigating increased expenses and competitive ...

Zai Lab Ltd's (NASDAQ:ZLAB) Chief Legal Officer, Edmondson Frazor Titus III, has engaged in recent trading activity involving the company's stock, according to a new SEC filing.

Q3 2024 Earnings Call Transcript October 31, 2024 Operator: Good morning. My name is Rob and I will be your conference ...

2359.HK WuXi AppTec Co., Ltd.

9995.HK RemeGen Co., Ltd.

Discover how argenx's strong Q3 results and promising pipeline are driving growth, despite high valuation after share price ...